Royalty Pharma Plc Cl A (RPRX)

$51.70 +0.05 (0.10%)
Market Cap 29.79B
Revenue (ttm) 2.38B
Net Income (ttm) 770.95M
EPS (ttm) N/A
PE Ratio 10.02
Forward PE 10.07
Profit Margin 32.42%
Debt to Equity Ratio 0.90
Volume 3,457,000
Avg Vol 3,306,318
Day's Range N/A - N/A
Shares Out 576.86M
Stochastic %K 85%
Beta 0.40
Analysts Strong Sell
Price Target $58.28

Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 883 0200
Address:
110 East 59th Street, New York, United States
OfficialStocktwitsUser
OfficialStocktwitsUser May. 7 at 8:39 PM
$RPRX RSI: 52.05, MACD: 0.8047 Vol: 0.72, MA20: 49.48, MA50: 47.74 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CapitalMonk
CapitalMonk May. 6 at 5:04 PM
$RPRX Price: $50.15 (-0.57%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±1.23% RSI: 64.2 | Momentum: Moderate Volume: -54.0% vs avg Volatility: 1.05% Support: $47.44 | Resistance: $51.65 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 11:38 AM
$RPRX Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.53 down -3.64% YoY • Reported revenue of $631M up 11.04% YoY • Royalty Pharma expects 2026 Portfolio Receipts to be between $3.33B and $3.45B, an increase from previous guidance, representing expected Royalty Receipts growth of 4% to 8%.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 3 at 3:09 PM
Attached is a history of the royalty accrual $SNDX is required to record as an estimate of the amounts they will owe $RPRX over the following 12-months. Be careful to simply take the accrual & divide by 13.8% because there may be minor details around the agreement that have not been disclosed. All we know with certainty is SNDX increased the interest rate on the RPRX transaction at the end of FY25. We're not experts but it is our experience (again without knowing the exact details), by itself, the higher rate means actual Niktimvo sales have been much higher than originally forecast. Again by itself, this is a good thing for Niktimvo valuation. This is also consistent with RPRX's 9/2025 report to its shareholders that Niktimvo projected 5-year sales as of 9/2025 were 98% higher than the same 5-year projection at the time RPRX made the investment in 11/2024. $INCY sells Niktimvo As always, we could be wrong. This is not investment advice. $XBI $IBB
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 21 at 7:47 PM
$RPRX Share Price: $49.49 Contract Selected: Oct 16, 2026 $50 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.03 – $2.48 Potential Upside: 51% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
WAJeff
WAJeff Apr. 17 at 9:33 PM
$RPRX sold $49.98, $50.01 52 week high
1 · Reply
ashutoshpangasa
ashutoshpangasa Apr. 10 at 2:59 PM
📈 Market Update: The "Ceasefire Cycle" & The AI Super-Cycle The April 8 ceasefire in the Middle East has triggered a massive rotation. Money is flowing out of Energy/War Hedges and directly into the AI & Connectivity infrastructure names on my watchlists. 🌍💻 🔥 Top Momentum Drivers: $AAOI / $GLW / $DELL: The AI Super-cycle is real. Meta’s $6B fiber deal and record AI server demand are pushing these into orbit. 🚀 $CIEN / $TIGO: Connectivity is the new gold. Double-digit revenue growth as 800G/1.6T ramps up. 🌐 $RPRX: Catching the "Peace Dividend" relief rally + huge $500M R&D news with J&J. 💊 🔄 The Portfolio Rotation: Bullish: Tech Infrastructure ($MRVL, $VRT) and Global Connectivity. Bearish: Energy Hedges ($CNQ, $OXY) as the "War Premium" evaporates. Strategy: Staying long on the "Picks & Shovels" of the AI build-out. The hardware bottleneck is the place to be. 🛠️💎
0 · Reply
zerodayrounder
zerodayrounder Apr. 7 at 12:29 AM
my $TBPH #s were a bit off .. i didn't fact check Gemini. Call it $1.8 billion total Theravance received. Trelegy royalty rate 6-8% on $3.5 billion annual sales $SPRO then is worth what to $GSK or $RPRX ? 2.5 billion peak sales from 2031-2041 -- 12% royalties over $1 billion -- minus whatever SPRO pays Meiji. https://gemini.google.com/share/273ee80740fa
1 · Reply
zerodayrounder
zerodayrounder Apr. 6 at 11:53 PM
$GSK would essentially be buying back the milestones and royalties it expects to owe $SPRO going out to 2041. If that number is $2-3 billion over the life of tebi -- perhaps spending 1/3rd of that amount today is worth it from a DCF perspective (and controlling a blockbuster drug) Similar to how GSK bought back the royalty stream it owed to $TBPH for Trelegy ... I think they paid $225 million in July 2025 for whatever royalties (the so-called "out years" in 2030/2031+) hadn't already been sold to $RPRX back in 2021
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 3 at 5:36 PM
The attachment notes the 22 commercial-stage bios trading within 10% of their highest closing share price since 12/1/2025 as of 4/2/2026. We count 89 such bios in total in this peer group (25 oncology focused with MCs over $300MM & 64 non-oncology focused with MCs over $800MM). $RPRX $KNSA $AGIO & $TGTX are the non-oncology bios in this peer group all trading at their highest share prices since 12/1/2025. $SNDX closed at its highest closing price in oncology. Thank you Goldman Sachs. SNDX investors may want to look at SNDX trading after Goldman's last upgrade that, our records reflect, was issued on 9/5/25. This is not investment advice.
1 · Reply
Latest News on RPRX
Royalty Pharma to present at upcoming investor conferences

May 7, 2026, 4:15 PM EDT - 5 days ago

Royalty Pharma to present at upcoming investor conferences

Royalty Pharma price target raised to $64 from $63 at Morgan Stanley

2026-05-07T19:05:03.000Z - 5 days ago

Royalty Pharma price target raised to $64 from $63 at Morgan Stanley

Royalty Pharma price target raised to $58 from $50 at JPMorgan

2026-05-07T15:26:17.000Z - 5 days ago

Royalty Pharma price target raised to $58 from $50 at JPMorgan

Royalty Pharma price target raised to $66 from $50 at Citi

2026-05-07T11:16:52.000Z - 6 days ago

Royalty Pharma price target raised to $66 from $50 at Citi

Royalty Pharma Earnings Call Transcript: Q1 2026

May 6, 2026, 8:00 AM EDT - 7 days ago

Royalty Pharma Earnings Call Transcript: Q1 2026

Royalty Pharma reports first quarter 2026 results

May 6, 2026, 7:00 AM EDT - 7 days ago

Royalty Pharma reports first quarter 2026 results

An 8-Hour AI Result Is Testing Pharma's $10 Billion Royalty Market

May 1, 2026, 12:00 PM EDT - 11 days ago

An 8-Hour AI Result Is Testing Pharma's $10 Billion Royalty Market

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

Apr 21, 2026, 1:00 PM EDT - 21 days ago

Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation

Royalty Pharma price target raised to $57 from $51 at UBS

2026-04-21T12:29:12.000Z - 22 days ago

Royalty Pharma price target raised to $57 from $51 at UBS

Royalty Pharma Declares Second Quarter 2026 Dividend

Apr 17, 2026, 8:30 AM EDT - 26 days ago

Royalty Pharma Declares Second Quarter 2026 Dividend

Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026

Apr 15, 2026, 4:15 PM EDT - 27 days ago

Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026

Royalty Pharma price target raised to $63 from $61 at Morgan Stanley

2026-04-10T13:01:22.000Z - 4 weeks ago

Royalty Pharma price target raised to $63 from $61 at Morgan Stanley

Royalty Pharma and J&J partner to develop autoimmune treatment

Mar 30, 2026, 9:14 AM EDT - 6 weeks ago

Royalty Pharma and J&J partner to develop autoimmune treatment

JNJ

Royalty Pharma reports co-funding agreement with Johnson & Johnson for JNJ-4804

2026-03-30T11:37:52.000Z - 6 weeks ago

Royalty Pharma reports co-funding agreement with Johnson & Johnson for JNJ-4804

JNJ

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Mar 30, 2026, 7:15 AM EDT - 6 weeks ago

Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

Mar 23, 2026, 7:15 AM EDT - 7 weeks ago

Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

Royalty Pharma Announces Expansion of Leadership Team

Mar 17, 2026, 4:01 PM EDT - 2 months ago

Royalty Pharma Announces Expansion of Leadership Team

Zymeworks price target raised to $48 from $33 at Evercore ISI

2026-03-09T12:10:52.000Z - 2 months ago

Zymeworks price target raised to $48 from $33 at Evercore ISI

ZYME

Royalty Pharma Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:10 PM EST - 2 months ago

Royalty Pharma Transcript: TD Cowen 46th Annual Health Care Conference

Royalty Pharma appoints Kenneth Sun as Senior Vice President, Head of Asia

2026-03-02T12:16:19.000Z - 2 months ago

Royalty Pharma appoints Kenneth Sun as Senior Vice President, Head of Asia

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

Mar 2, 2026, 7:00 AM EST - 2 months ago

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

Zymeworks, Royalty Pharma enter $250M royalty-backed note financing

2026-03-02T11:15:10.000Z - 2 months ago

Zymeworks, Royalty Pharma enter $250M royalty-backed note financing

JAZZ ONC ZYME

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Mar 2, 2026, 6:10 AM EST - 2 months ago

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Royalty Pharma price target raised to $50 from $45 at TD Cowen

2026-02-27T18:55:35.000Z - 2 months ago

Royalty Pharma price target raised to $50 from $45 at TD Cowen

Royalty Pharma to Present at TD Cowen's 46th Annual Health Care Conference

Feb 26, 2026, 4:15 PM EST - 2 months ago

Royalty Pharma to Present at TD Cowen's 46th Annual Health Care Conference

Royalty Pharma price target raised to $51 from $45 at Goldman Sachs

2026-02-12T13:38:41.000Z - 3 months ago

Royalty Pharma price target raised to $51 from $45 at Goldman Sachs

Royalty Pharma price target raised to $61 from $56 at Morgan Stanley

2026-02-12T13:15:29.000Z - 3 months ago

Royalty Pharma price target raised to $61 from $56 at Morgan Stanley

Royalty Pharma Earnings Call Transcript: Q4 2025

Feb 11, 2026, 8:00 AM EST - 3 months ago

Royalty Pharma Earnings Call Transcript: Q4 2025

Royalty Pharma sees FY26 portfolio receipts $3.275B-3.425B

2026-02-11T12:15:33.000Z - 3 months ago

Royalty Pharma sees FY26 portfolio receipts $3.275B-3.425B

Royalty Pharma reports Q4 portfolio receipts of $874M

2026-02-11T12:06:08.000Z - 3 months ago

Royalty Pharma reports Q4 portfolio receipts of $874M

Royalty Pharma Reports Q4 and Full Year 2025 Results

Feb 11, 2026, 7:00 AM EST - 3 months ago

Royalty Pharma Reports Q4 and Full Year 2025 Results

Royalty Pharma upgraded to Buy from Neutral at UBS

2026-01-30T09:45:21.000Z - 3 months ago

Royalty Pharma upgraded to Buy from Neutral at UBS

Royalty Pharma price target raised to $50 from $48 at Citi

2026-01-27T11:45:48.000Z - 3 months ago

Royalty Pharma price target raised to $50 from $48 at Citi

Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

Jan 20, 2026, 4:15 PM EST - 4 months ago

Royalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

Royalty Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 12:45 PM EST - 4 months ago

Royalty Pharma Transcript: 44th Annual J.P. Morgan Healthcare Conference

Royalty Pharma provides update on business performance

2026-01-12T12:36:22.000Z - 4 months ago

Royalty Pharma provides update on business performance

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:15 AM EST - 4 months ago

Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference

Royalty Pharma, Teva enter agreement to accelerate development of TEV-‘408

2026-01-11T22:20:07.000Z - 4 months ago

Royalty Pharma, Teva enter agreement to accelerate development of TEV-‘408

TEVA

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Jan 11, 2026, 5:15 PM EST - 4 months ago

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

Royalty Pharma board increases quarterly dividend 6.8% to 23.5c per share

2026-01-09T13:45:57.000Z - 4 months ago

Royalty Pharma board increases quarterly dividend 6.8% to 23.5c per share

Royalty Pharma Announces Dividend Increase

Jan 9, 2026, 8:30 AM EST - 4 months ago

Royalty Pharma Announces Dividend Increase

Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones

Dec 29, 2025, 4:40 PM EST - 4 months ago

Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones

Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million

Dec 16, 2025, 7:15 AM EST - 5 months ago

Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

Dec 4, 2025, 7:10 AM EST - 5 months ago

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

Dec 4, 2025, 7:00 AM EST - 5 months ago

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

DNLI

Royalty Pharma Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 3:50 PM EST - 5 months ago

Royalty Pharma Transcript: Evercore ISI 8th Annual HealthCONx Conference

Royalty Pharma Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 3:15 PM EST - 5 months ago

Royalty Pharma Transcript: Citi Annual Global Healthcare Conference 2025

Royalty Pharma to Present at Upcoming Investor Conferences

Nov 26, 2025, 8:15 AM EST - 5 months ago

Royalty Pharma to Present at Upcoming Investor Conferences

Royalty Pharma Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:00 AM EST - 6 months ago

Royalty Pharma Earnings Call Transcript: Q3 2025

Royalty Pharma Reports Third Quarter 2025 Results

Nov 5, 2025, 7:00 AM EST - 6 months ago

Royalty Pharma Reports Third Quarter 2025 Results

Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences

Nov 4, 2025, 7:15 AM EST - 6 months ago

Royalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life Sciences

Royalty Pharma Declares Fourth Quarter 2025 Dividend

Oct 17, 2025, 8:15 AM EDT - 7 months ago

Royalty Pharma Declares Fourth Quarter 2025 Dividend

Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025

Oct 9, 2025, 4:15 PM EDT - 7 months ago

Royalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025

Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

Sep 29, 2025, 8:15 AM EDT - 8 months ago

Royalty Pharma Appoints Dr. Ted W. Love As Lead Independent Director

Royalty Pharma Transcript: Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Sep 23, 2025, 2:50 PM EDT - 8 months ago

Royalty Pharma Transcript: Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum

Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum

Sep 19, 2025, 4:25 PM EDT - 8 months ago

Royalty Pharma to Present at Bernstein's 2nd Annual Healthcare Forum

Royalty Pharma Transcript: Investor Day 2025

Sep 11, 2025, 8:30 AM EDT - 8 months ago

Royalty Pharma Transcript: Investor Day 2025

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation

Sep 11, 2025, 7:00 AM EDT - 8 months ago

Royalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value Creation

Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market

Sep 10, 2025, 7:30 AM EDT - 8 months ago

Royalty Pharma Announces Release of Deloitte's Report on the Biopharma Royalty Market

Royalty Pharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 3:20 PM EDT - 8 months ago

Royalty Pharma Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 4, 2025, 4:15 PM EDT - 8 months ago

Royalty Pharma to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

Sep 2, 2025, 8:30 PM EDT - 9 months ago

Royalty Pharma Announces Pricing of $2.0 Billion of Senior Unsecured Notes

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

Sep 2, 2025, 7:15 AM EDT - 9 months ago

Royalty Pharma and Zenas BioPharma Enter Into Obexelimab Funding Agreement for Up to $300 Million

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

Sep 2, 2025, 7:05 AM EDT - 9 months ago

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

ZBIO

Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million

Aug 25, 2025, 6:33 AM EDT - 9 months ago

Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million

AMGN

Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million

Aug 25, 2025, 6:10 AM EDT - 9 months ago

Royalty Pharma to Acquire Royalty Interest in Amgen's Imdelltra for up to $950 Million

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

Aug 25, 2025, 6:00 AM EDT - 9 months ago

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

ONC

Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

Aug 13, 2025, 4:15 PM EDT - 9 months ago

Henry Fernandez Steps Down from Royalty Pharma's Board of Directors

Royalty Pharma Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 10 months ago

Royalty Pharma Earnings Call Transcript: Q2 2025

Royalty Pharma Reports Second Quarter 2025 Results

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Royalty Pharma Reports Second Quarter 2025 Results

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 10 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 10 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Royalty Pharma Declares Third Quarter 2025 Dividend

Jul 18, 2025, 8:15 AM EDT - 10 months ago

Royalty Pharma Declares Third Quarter 2025 Dividend

Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors

Jul 17, 2025, 8:15 AM EDT - 10 months ago

Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors

Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025

Jul 16, 2025, 4:15 PM EDT - 10 months ago

Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

Jun 24, 2025, 7:19 AM EDT - 11 months ago

Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug

RVMD

Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

Jun 24, 2025, 7:05 AM EDT - 11 months ago

Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion

Royalty Pharma Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 2:00 PM EDT - 1 year ago

Royalty Pharma Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 4:15 PM EDT - 1 year ago

Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Royalty Pharma Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 20, 2025, 4:05 PM EDT - 1 year ago

Royalty Pharma Transcript: RBC Capital Markets Global Healthcare Conference 2025

Royalty Pharma Completes the Acquisition of Its External Manager

May 16, 2025, 4:30 PM EDT - 1 year ago

Royalty Pharma Completes the Acquisition of Its External Manager

Royalty Pharma Transcript: Bank of America 2025 Healthcare Conference

May 14, 2025, 5:20 PM EDT - 1 year ago

Royalty Pharma Transcript: Bank of America 2025 Healthcare Conference

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

May 12, 2025, 4:15 PM EDT - 1 year ago

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

OfficialStocktwitsUser
OfficialStocktwitsUser May. 7 at 8:39 PM
$RPRX RSI: 52.05, MACD: 0.8047 Vol: 0.72, MA20: 49.48, MA50: 47.74 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CapitalMonk
CapitalMonk May. 6 at 5:04 PM
$RPRX Price: $50.15 (-0.57%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±1.23% RSI: 64.2 | Momentum: Moderate Volume: -54.0% vs avg Volatility: 1.05% Support: $47.44 | Resistance: $51.65 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 6 at 11:38 AM
$RPRX Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.53 down -3.64% YoY • Reported revenue of $631M up 11.04% YoY • Royalty Pharma expects 2026 Portfolio Receipts to be between $3.33B and $3.45B, an increase from previous guidance, representing expected Royalty Receipts growth of 4% to 8%.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 3 at 3:09 PM
Attached is a history of the royalty accrual $SNDX is required to record as an estimate of the amounts they will owe $RPRX over the following 12-months. Be careful to simply take the accrual & divide by 13.8% because there may be minor details around the agreement that have not been disclosed. All we know with certainty is SNDX increased the interest rate on the RPRX transaction at the end of FY25. We're not experts but it is our experience (again without knowing the exact details), by itself, the higher rate means actual Niktimvo sales have been much higher than originally forecast. Again by itself, this is a good thing for Niktimvo valuation. This is also consistent with RPRX's 9/2025 report to its shareholders that Niktimvo projected 5-year sales as of 9/2025 were 98% higher than the same 5-year projection at the time RPRX made the investment in 11/2024. $INCY sells Niktimvo As always, we could be wrong. This is not investment advice. $XBI $IBB
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 21 at 7:47 PM
$RPRX Share Price: $49.49 Contract Selected: Oct 16, 2026 $50 Calls Buy Zone: $1.27 – $1.58 Target Zone: $2.03 – $2.48 Potential Upside: 51% ROI Time to Expiration: 177 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
WAJeff
WAJeff Apr. 17 at 9:33 PM
$RPRX sold $49.98, $50.01 52 week high
1 · Reply
ashutoshpangasa
ashutoshpangasa Apr. 10 at 2:59 PM
📈 Market Update: The "Ceasefire Cycle" & The AI Super-Cycle The April 8 ceasefire in the Middle East has triggered a massive rotation. Money is flowing out of Energy/War Hedges and directly into the AI & Connectivity infrastructure names on my watchlists. 🌍💻 🔥 Top Momentum Drivers: $AAOI / $GLW / $DELL: The AI Super-cycle is real. Meta’s $6B fiber deal and record AI server demand are pushing these into orbit. 🚀 $CIEN / $TIGO: Connectivity is the new gold. Double-digit revenue growth as 800G/1.6T ramps up. 🌐 $RPRX: Catching the "Peace Dividend" relief rally + huge $500M R&D news with J&J. 💊 🔄 The Portfolio Rotation: Bullish: Tech Infrastructure ($MRVL, $VRT) and Global Connectivity. Bearish: Energy Hedges ($CNQ, $OXY) as the "War Premium" evaporates. Strategy: Staying long on the "Picks & Shovels" of the AI build-out. The hardware bottleneck is the place to be. 🛠️💎
0 · Reply
zerodayrounder
zerodayrounder Apr. 7 at 12:29 AM
my $TBPH #s were a bit off .. i didn't fact check Gemini. Call it $1.8 billion total Theravance received. Trelegy royalty rate 6-8% on $3.5 billion annual sales $SPRO then is worth what to $GSK or $RPRX ? 2.5 billion peak sales from 2031-2041 -- 12% royalties over $1 billion -- minus whatever SPRO pays Meiji. https://gemini.google.com/share/273ee80740fa
1 · Reply
zerodayrounder
zerodayrounder Apr. 6 at 11:53 PM
$GSK would essentially be buying back the milestones and royalties it expects to owe $SPRO going out to 2041. If that number is $2-3 billion over the life of tebi -- perhaps spending 1/3rd of that amount today is worth it from a DCF perspective (and controlling a blockbuster drug) Similar to how GSK bought back the royalty stream it owed to $TBPH for Trelegy ... I think they paid $225 million in July 2025 for whatever royalties (the so-called "out years" in 2030/2031+) hadn't already been sold to $RPRX back in 2021
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 3 at 5:36 PM
The attachment notes the 22 commercial-stage bios trading within 10% of their highest closing share price since 12/1/2025 as of 4/2/2026. We count 89 such bios in total in this peer group (25 oncology focused with MCs over $300MM & 64 non-oncology focused with MCs over $800MM). $RPRX $KNSA $AGIO & $TGTX are the non-oncology bios in this peer group all trading at their highest share prices since 12/1/2025. $SNDX closed at its highest closing price in oncology. Thank you Goldman Sachs. SNDX investors may want to look at SNDX trading after Goldman's last upgrade that, our records reflect, was issued on 9/5/25. This is not investment advice.
1 · Reply
ajb_2010
ajb_2010 Apr. 2 at 3:26 PM
$XBI biotech ETF range bound but strong sector to hide out nice chart on $RPRX $SPY
0 · Reply
MorganHoratio
MorganHoratio Mar. 31 at 1:10 PM
$SYRE Big biotech read-through most are sleeping on: BTIG just reiterated Buy / $70 PT after $RPRX + $JNJ teamed up on JNJ-4804 (dual IL-23 + TNF approach). That’s not just noise — it validates the combo therapy thesis in IBD, exactly where $SYRE is positioning. Why it matters: Big Pharma doubling down on multi-pathway biology Direct sympathy to $SYRE’s SPY120/130/230 combo platform DUET data from $JNJ later this year = potential sentiment catalyst Pipeline timeline: 2Q26: SPY001 (anti-CD47) PoC readout 2026: SPY002 (TL1A) + SPY003 (IL-23) data follow 2027: Full Phase 2 combo data (SKYLINE) Underrated angle: TL1A is part of the TNF superfamily — historically validated pathways = higher probability setups. If TNF worked, TL1A could be next. More shots on goal: 3Q26: SPY072 (RA) 4Q26: axSpA + PsA data Translation: This isn’t a single binary biotech — it’s a platform bet with multiple catalysts lined up. Market hasn’t fully priced this in yet. Stay alert.
0 · Reply
Quantumup
Quantumup Mar. 31 at 11:41 AM
BTIG reiterated $SYRE Buy-$70 after $RPRX announced a co-funding agreement w/ $JNJ for the devt of JNJ-4804 (co-antibody of remfya+golimumab [IL-23+TNF]). Here's what BTIG had to say in its note: https://x.com/Quantumup1/status/2038944109151261006?s=20
0 · Reply
zerodayrounder
zerodayrounder Mar. 26 at 1:10 PM
so $TBPH sold its Trelegy royalty rights to $RPRX for $1.1 billion in 2022 (and retained "late-stage" royalties and milestones from Royalty Pharma if certain sales targets hit). In July 2025, TBPH sold its remaining "late stage" royalties to $GSK for $225 million. The Trelegy patent is supposed to end around 2031 and is a blockbuster for GSK. At one point, GSK owned 27% of TBPH but never purchased it outright -- although there was speculation it would 15 years ago. TBPH had multiple other drugs etc and wasn't basically just a one-drug royalty/shell company that has ceased new drug development like $SPRO ... Perhaps $GSK will take $SPRO in-house to avoid royalties like it did to clean up Trelegy royalty stream still retained by TBPH. https://gemini.google.com/share/4b89dc8a9570
1 · Reply
WAJeff
WAJeff Mar. 25 at 11:31 PM
Added $RPRX $47
0 · Reply
StockConsultant
StockConsultant Mar. 25 at 10:55 PM
$RPRX Royalty Pharma stock, nice rally off the 45.64 triple support area, breakout watch, from Stocks to Watch at https://stockconsultant.com/?RPRX
0 · Reply
JuggernautRaider
JuggernautRaider Mar. 11 at 2:56 PM
$FBIO don’t be shocked if the sell the CUTX-101 royalty stream to $RPRX for a nice premium 🚀
1 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 11:34 PM
$RPRX Current Stock Price: $45.97 Contracts to trade: $45.0 RPRX Mar 20 2026 Call Entry: $1.20 Exit: $1.92 ROI: 60% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
BioTechHealthX
BioTechHealthX Mar. 8 at 4:29 PM
$RPRX Royalty Pharma Plc (NASDAQ: RPRX) is quietly becoming one of the most intriguing cheap biotech stocks as its royalty-based business model generates recurring revenue from blockbuster medicines. With analysts raising price targets and the company holding billions in financial firepower for new acquisitions, RPRX stock could offer investors exposure to biotech growth without the typical drug development risks. https://biotechhealthx.com/biotech-news/is-it-a-wise-move-to-buy-royalty-pharma-rprx-shares/
0 · Reply
JuggernautRaider
JuggernautRaider Mar. 6 at 3:00 PM
$FBIO anyone else wondering if they’ll sell tbe CUTX-101 royalty stream to $RPRX ? 🧐
0 · Reply
TechridyStocks
TechridyStocks Mar. 6 at 1:39 AM
$RPRX still solid
0 · Reply
OpenOutcrier
OpenOutcrier Mar. 2 at 1:39 PM
$RPRX (-7.2% pre) $ZYME (-3.3% pre) Ziihera cancer drug sparks $250M Royalty Pharma–Zymeworks deal https://ooc.bz/l/95120
0 · Reply